<?xml version="1.0" encoding="UTF-8" standalone="no"?><document setID="44c45bfe-461f-4398-8f20-ea771b2403ee"><labelDrug name="NATRECOR"><Normalization><mmtx cui="C1170421" preferredWord="Natrecor" semType="phsu, aapp"/></Normalization></labelDrug><generic name="NESIRITIDE"/><sentence id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.1" text="NATRECOR (nesiritide) injection, powder, lyophilized, for solution" type="negative"><entity charOffset="0:8" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.1.e.0" text="natrecor" type="Biomedical_Entity"><Normalization><mmtx cui="C1170421" phraseText="NATRECOR" preferredWord="Natrecor" semType="phsu, aapp"/><RxNorm RxCui="352791"/></Normalization></entity><entity charOffset="10:20" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.1.e.1" text="nesiritide" type="Biomedical_Entity"><Normalization><mmtx cui="C0054015" phraseText="(nesiritide" preferredWord="Nesiritide" semType="phsu, aapp, horm"/><RxNorm RxCui="19666"/></Normalization></entity><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.1.e.0" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.1.e.1"/></sentence><sentence id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.10" text="In the ASCEND-HF trial, the incidence of symptomatic hypotension was 7.1% in NATRECOR-treated patients compared to 4.0% in placebo-treated patients on a background of standard care. " type="negative"><entity charOffset="7:13" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.10.e.0" text="ascend" type="Biomedical_Entity"><Normalization><mmtx cui="C0308355" phraseText="ASCEND-" preferredWord="ASCEND (veterinary product)" semType="phsu, orch"/><RxNorm RxCui="1191349"/></Normalization></entity><entity charOffset="77:85" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.10.e.1" text="natrecor" type="Biomedical_Entity"><Normalization><mmtx cui="C1170421" phraseText="7.1% in NATRECOR-treated patients" preferredWord="Natrecor" semType="phsu, aapp"/><RxNorm RxCui="352791"/></Normalization></entity><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.10.e.0" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.10.e.1"/></sentence><sentence biomedicalEntities="5" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11" lineNumber="15" text="The risk of hypotension may be increased by the concomitant use of NATRECOR with drugs affecting the renin-angiotensin system (i.e., angiotensin receptor blockers and/or angiotensin-converting enzyme inhibitors) or other afterload reducers. " type="regular"><entity charOffset="12:23" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.0" text="hypotension" type="Specific_Interaction"/><entity charOffset="67:75" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.2" text="NATRECOR" type="Drug"><Normalization><mmtx cui="C1170421" phraseText="increased by the concomitant use of NATRECOR" preferredWord="Natrecor" semType="phsu, aapp"/><RxNorm RxCui="352791"/></Normalization></entity><entity charOffset="81:125" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.3" text="drugs affecting the renin-angiotensin system" type="Drug_Class"><Normalization><mmtx cui="C0013227" phraseText="with drugs" preferredWord="Pharmaceutical Preparations" semType="phsu"/><mmtx cui="C0035100" phraseText="the renin-angiotensin system" preferredWord="Chymosin" semType="phsu, aapp, enzy"/><mmtx cui="C0003018" phraseText="the renin-angiotensin system" preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="133:162" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.4" text="angiotensin receptor blockers" type="Drug_Class"><Normalization><mmtx cui="C0521942" phraseText="(i.e., angiotensin receptor blockers" preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><mmtx cui="C0815017" phraseText="(i.e., angiotensin receptor blockers" preferredWord="Angiotensin Receptor Antagonists" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="170:210" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.5" text="angiotensin-converting enzyme inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0003015" phraseText="angiotensin-converting enzyme inhibitors" preferredWord="Angiotensin-Converting Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="6162"/></Normalization></entity><entity charOffset="221:239" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.8" text="afterload reducers" type="Drug_Class"><Normalization><RxNorm RxCui="NA"/></Normalization></entity><classClassMembership drugClass="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.4"/><classClassMembership drugClass="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.5"/><drugInteraction id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.ddi.1"><interaction trigger="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.8"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.4"/></relation><relation type="hasObject"><entity id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.5"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.2" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.8" trigger="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.0" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.2" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.4" trigger="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.0" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.2" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.5" trigger="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.0" type="Specific_Interaction"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.4" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.8"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.5" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.8"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.4" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.11.e.5"/></sentence><sentence id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.12" text="In the VMAC trial, in patients given the recommended dose (2 mcg/kg bolus followed by a 0.01 mcg/kg/min infusion) or the adjustable dose, the incidence of symptomatic hypotension in the first 24 hours was similar for NATRECOR (4%) and IV nitroglycerin (5%). " type="negative"><entity charOffset="238:251" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.12.e.0" text="nitroglycerin" type="Biomedical_Entity"><Normalization><mmtx cui="C0885378" phraseText="IV nitroglycerin" preferredWord="Glonoine, nitroglycerine, Homeopathic preparation" semType="phsu, orch"/><RxNorm RxCui="4917"/></Normalization></entity><entity charOffset="217:225" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.12.e.1" text="natrecor" type="Biomedical_Entity"><Normalization><mmtx cui="C1170421" phraseText="similar for NATRECOR" preferredWord="Natrecor" semType="phsu, aapp"/><RxNorm RxCui="352791"/></Normalization></entity><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.12.e.1" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.12.e.0"/></sentence><sentence id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.13" text="When hypotension occurred, however, the duration of symptomatic hypotension was longer with NATRECOR (mean duration was 2.2 hours) than with nitroglycerin (mean duration was 0.7 hours)." type="negative"><entity charOffset="141:154" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.13.e.0" text="nitroglycerin" type="Biomedical_Entity"><Normalization><mmtx cui="C0885378" phraseText="with nitroglycerin" preferredWord="Glonoine, nitroglycerine, Homeopathic preparation" semType="phsu, orch"/><RxNorm RxCui="4917"/></Normalization></entity><entity charOffset="92:100" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.13.e.1" text="natrecor" type="Biomedical_Entity"><Normalization><mmtx cui="C1170421" phraseText="longer with NATRECOR" preferredWord="Natrecor" semType="phsu, aapp"/><RxNorm RxCui="352791"/></Normalization></entity><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.13.e.1" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.13.e.0"/></sentence><sentence id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.17" text="NATRECOR is not recommended for patients for whom vasodilating agents are not appropriate, such as patients with significant valvular stenosis, restrictive or obstructive cardiomyopathy, constrictive pericarditis, pericardial tamponade, or other conditions in which cardiac output is dependent upon venous return, or for patients suspected to have low cardiac filling pressures [see Contraindications (4)]." type="negative"><entity charOffset="0:8" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.17.e.0" text="natrecor" type="Biomedical_Entity"><Normalization><mmtx cui="C1170421" phraseText="NATRECOR" preferredWord="Natrecor" semType="phsu, aapp"/><RxNorm RxCui="352791"/></Normalization></entity><entity charOffset="50:69" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.17.e.1" text="vasodilating agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0042402" phraseText="for whom vasodilating agents" preferredWord="Vasodilator Agents" semType="phsu"/><RxNorm RxCui="11146"/></Normalization></entity><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.17.e.0" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.17.e.1"/></sentence><sentence id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.22" text="In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin aldosterone system, treatment with NATRECOR may be associated with azotemia. " type="negative"><entity charOffset="99:110" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.22.e.0" text="angiotensin" type="Biomedical_Entity"><Normalization><mmtx cui="C0003018" phraseText="depend on the activity of the renin-angiotensin aldosterone system," preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="111:122" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.22.e.1" text="aldosterone" type="Biomedical_Entity"><Normalization><mmtx cui="C0002006" phraseText="depend on the activity of the renin-angiotensin aldosterone system," preferredWord="Aldosterone" semType="strd, phsu, horm"/><RxNorm RxCui="1312358"/></Normalization></entity><entity charOffset="146:154" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.22.e.2" text="natrecor" type="Biomedical_Entity"><Normalization><mmtx cui="C1170421" phraseText="treatment with NATRECOR" preferredWord="Natrecor" semType="phsu, aapp"/><RxNorm RxCui="352791"/></Normalization></entity><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.22.e.0" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.22.e.1"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.22.e.0" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.22.e.2"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.22.e.1" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.22.e.2"/></sentence><sentence id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29" text="Some serious hypersensitivity/allergic reactions may require treatment with epinephrine, oxygen, IV fluids, antihistamines, corticosteroids, pressor amines and airway management, as clinically indicated." type="negative"><entity charOffset="108:122" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29.e.0" text="antihistamines" type="Biomedical_Entity"><Normalization><mmtx cui="C0019590" phraseText="antihistamines," preferredWord="Histamine Antagonists" semType="phsu, orch"/><RxNorm RxCui="967"/></Normalization></entity><entity charOffset="76:87" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29.e.1" text="epinephrine" type="Biomedical_Entity"><Normalization><mmtx cui="C0014563" phraseText="treatment with epinephrine," preferredWord="Epinephrine" semType="phsu, orch, horm, nsba"/><RxNorm RxCui="362"/></Normalization></entity><entity charOffset="124:139" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29.e.2" text="corticosteroids" type="Biomedical_Entity"><Normalization><mmtx cui="C0001617" phraseText="corticosteroids," preferredWord="Adrenal Cortex Hormones" semType="strd, phsu, horm"/><RxNorm RxCui="1427675"/></Normalization></entity><entity charOffset="141:148" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29.e.3" text="pressor" type="Biomedical_Entity"><Normalization><mmtx cui="C0237795" phraseText="pressor amines" preferredWord="Pressors" semType="phsu"/><RxNorm RxCui="203344"/></Normalization></entity><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29.e.1" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29.e.0"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29.e.0" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29.e.2"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29.e.0" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29.e.3"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29.e.1" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29.e.2"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29.e.1" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29.e.3"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29.e.2" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.29.e.3"/></sentence><sentence id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.31" text="No trials specifically examining potential drug interactions with NATRECOR  were conducted, although many concomitant drugs (including IV nitroglycerin) were used in clinical trials [see Clinical Studies (14)]. " type="negative"><entity charOffset="138:151" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.31.e.0" text="nitroglycerin" type="Biomedical_Entity"><Normalization><mmtx cui="C0885378" phraseText="IV nitroglycerin" preferredWord="Glonoine, nitroglycerine, Homeopathic preparation" semType="phsu, orch"/><RxNorm RxCui="4917"/></Normalization></entity><entity charOffset="66:74" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.31.e.1" text="natrecor" type="Biomedical_Entity"><Normalization><mmtx cui="C1170421" phraseText="potential drug interactions with NATRECOR" preferredWord="Natrecor" semType="phsu, aapp"/><RxNorm RxCui="352791"/></Normalization></entity><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.31.e.1" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.31.e.0"/></sentence><sentence biomedicalEntities="4" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32" lineNumber="35" text="No drug interactions were detected except for an increase in symptomatic hypotension in patients receiving afterload reducers or affecting the renin-angiotensin system (i.e., ARBs and/or ACE inhibitors)." type="irregular"><entity charOffset="61:84" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.0" text="symptomatic hypotension" type="Specific_Interaction"/><entity charOffset="107:125" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.2" text="afterload reducers" type="Drug_Class"><Normalization><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="129:167" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.3" text="affecting the renin-angiotensin system" type="Drug_Class"><Normalization><mmtx cui="C0035100" phraseText="the renin-angiotensin system" preferredWord="Chymosin" semType="phsu, aapp, enzy"/><mmtx cui="C0003018" phraseText="the renin-angiotensin system" preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="989956"/></Normalization></entity><entity charOffset="175:179" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.4" text="ARBs" type="Drug_Class"><Normalization><RxNorm RxCui="1149617"/></Normalization></entity><entity charOffset="187:201" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.5" text="ACE inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0003015" phraseText="ACE inhibitors" preferredWord="Angiotensin-Converting Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="221294"/></Normalization></entity><classClassMembership drugClass="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.4"/><classClassMembership drugClass="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.5"/><drugInteraction id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.ddi.1"><interaction trigger="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.2"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.31" text="No trials specifically examining potential drug interactions with NATRECOR  were conducted, although many concomitant drugs (including IV nitroglycerin) were used in clinical trials [see Clinical Studies (14)]. "><entity charOffset="66:74" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.31.e.0" text="NATRECOR" type="Drug"><Normalization><mmtx cui="C1170421" phraseText="potential drug interactions with NATRECOR" preferredWord="Natrecor" semType="phsu, aapp"/><mmtx cui="C1170421" phraseText="potential drug interactions with NATRECOR" preferredWord="Natrecor" semType="phsu, aapp"/></Normalization></entity></ellipsisSentence></relation><relation type="hasPrecipitant"><entity id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.5"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.4"/></relation></relations></interaction></drugInteraction><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.2" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.5"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.2" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.4"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.4" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.5"/><pair ddi="true" e1="labelDrug" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.2"/><pair ddi="true" e1="labelDrug" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.5"/><pair ddi="true" e1="labelDrug" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.32.e.4"/></sentence><sentence id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33" text="The co-administration of NATRECOR  with nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated." type="negative"><entity charOffset="40:53" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33.e.0" text="nitroprusside" type="Biomedical_Entity"><Normalization><mmtx cui="C0028193" phraseText="with nitroprusside," preferredWord="Nitroprusside" semType="inch, phsu"/><RxNorm RxCui="7476"/></Normalization></entity><entity charOffset="25:33" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33.e.1" text="natrecor" type="Biomedical_Entity"><Normalization><mmtx cui="C1170421" phraseText="The co-administration of NATRECOR" preferredWord="Natrecor" semType="phsu, aapp"/><RxNorm RxCui="352791"/></Normalization></entity><entity charOffset="72:86" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33.e.2" text="ace inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C0003015" phraseText="IV ACE inhibitors" preferredWord="Angiotensin-Converting Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="221294"/></Normalization></entity><entity charOffset="55:64" id="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33.e.3" text="milrinone" type="Biomedical_Entity"><Normalization><mmtx cui="C0128513" phraseText="milrinone," preferredWord="Milrinone" semType="phsu, orch"/><RxNorm RxCui="155120"/></Normalization></entity><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33.e.1" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33.e.0"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33.e.0" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33.e.2"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33.e.0" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33.e.3"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33.e.1" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33.e.2"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33.e.1" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33.e.3"/><pair ddi="false" e1="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33.e.3" e2="Dailymed.44c45bfe-461f-4398-8f20-ea771b2403ee.s.33.e.2"/></sentence><positiveExamples number="6"/><negativeExamples number="27"/></document>